BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mishra R, Yuan L, Patel H, Karve AS, Zhu H, White A, Alanazi S, Desai P, Merino EJ, Garrett JT. Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. Int J Mol Sci 2021;22:2088. [PMID: 33669867 DOI: 10.3390/ijms22042088] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. Int J Mol Sci 2021;22:3464. [PMID: 33801659 DOI: 10.3390/ijms22073464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wang T, Zou J, Wu Q, Wang R, Yuan CL, Shu J, Zhai BB, Huang XT, Liu NZ, Hua FY, Wang XC, Mei WJ. Tanshinone IIA derivatives induced S-phase arrest through stabilizing c-myc G-quadruplex DNA to regulate ROS-mediated PI3K/Akt/mTOR pathway. Eur J Pharmacol 2021;912:174586. [PMID: 34710368 DOI: 10.1016/j.ejphar.2021.174586] [Reference Citation Analysis]
3 Peng Y, Yu H, Jin Y, Qu F, Ren H, Tang Z, Zhang Y, Qu C, Zong B, Liu S. Construction and Validation of an Immune Infiltration-Related Gene Signature for the Prediction of Prognosis and Therapeutic Response in Breast Cancer. Front Immunol 2021;12:666137. [PMID: 33986754 DOI: 10.3389/fimmu.2021.666137] [Cited by in F6Publishing: 1] [Reference Citation Analysis]